Positive VIMPAT (lacosamide) monotherapy Phase III Trial Results Presented at European Academy of Neurology Congress
May 30, 2016
May 30, 2016
BRUSSELS, May 30 -- UCB issued the following news release:
New clinical trial data, presented at the second Congress of the European Academy of Neurology (EAN), showed non-inferiority of lacosamide (VIMPAT) monotherapy compared with controlled-release carbamazepine among patients with newly or recently diagnosed focal epilepsy.
The results are from a Phase III international, double-blind, randomized, active-controlled trial, the fourth in a series of non-inferiority . . .
New clinical trial data, presented at the second Congress of the European Academy of Neurology (EAN), showed non-inferiority of lacosamide (VIMPAT) monotherapy compared with controlled-release carbamazepine among patients with newly or recently diagnosed focal epilepsy.
The results are from a Phase III international, double-blind, randomized, active-controlled trial, the fourth in a series of non-inferiority . . .